SAB Biotherapeutics (SABS) Convertible Debt (2022 - 2023)

SAB Biotherapeutics (SABS) reported Convertible Debt of $541644.0 for Q2 2023, little changed quarter-over-quarter from $541644.0 in Q1 2023.

SAB Biotherapeutics (SABS) Convertible Debt (2022 - 2023) Analysis & Trends

SAB Biotherapeutics has reported Convertible Debt for 2 years, with the latest figure at $541644.0 in Q2 2023.

For the quarter ending Q2 2023, Convertible Debt changed N/A year-over-year to $541644.0; the trailing twelve-month figure through Jun 2023 stood at $541644.0 (changed N/A YoY), and the FY2022 full-year result was $541644.0, changed N/A from the prior year.
Convertible Debt for Q2 2023 stood at $541644.0, roughly flat from $541644.0 in the prior quarter.
The five-year high for Convertible Debt was $541644.0 in Q4 2022, with the low at $541644.0 in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	SAB Biotherapeutics	214.77 Mn	214.77 Mn	-

Download Data